MediPharm Labs Corp.

LABS.TOTSXHealthcare● Active

$0.07

$-0.00(-0.00%)

Market Cap$29740480

P/E Ratio—

52W High$0.1

52W Low$0.06

Avg Volume302K

Open$0.08

Beta0.89

Free Cash Flow Financials Revenue

MediPharm Labs Corp. (LABS.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

LABS.TO · free cash flow · updated Jun 8, 2026

Core FCF metrics

LABS.TO · FCF · TTM · margin & CAGR

Free cash flow was −$5.6M for FY2025 (fiscal year ending 2025-12-31), down 11.7% year-over-year The FCF margin was -12.4%.

FY2025 Free Cash Flow−$5.6M▼ -11.7% YoY

Trailing 12M (TTM)−$3.3Mtrailing 4 quarters sum

FCF Margin-12.4%−$5.6M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

LABS.TO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$5.5M(0M)−$5.6M▼ 11.7%-12.4%

FY2024−$4.9M(0M)−$5.0M▲ +60.9%-11.9%

FY2023−$12.3M(0M)−$12.8M▲ +24.3%-38.8%

FY2022−$16.1M(1M)−$16.9M▼ 21.0%-76.6%

FY2021−$13.2M(1M)−$14.0M▲ +69.1%-64.5%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

LABS.TO · P/FCF · FCF yield · FCF per share

MediPharm Labs Corp. (LABS.TO) reported negative free cash flow of −$0.01B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

LABS.TO · cash flow statement · operating / investing / financing

For FY2025, MediPharm Labs Corp. generated −$5.5M in operating cash flow and spent 0M in capital expenditures, yielding −$5.6M in free cash flow.

Operating Activities

−$5.5M

Cash from core business operations

2025-12-31

Investing Activities

+$4.6M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$0.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$5.5M) − |CapEx| (0M) = FCF (−$5.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

LABS.TO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

MediPharm Labs Corp.YOU

LABS.TO

−$5.6M-11.7%-12.4%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

MediPharm Labs Corp. (LABS.TO) reported free cash flow of −$5.6M for FY2025 (fiscal year ending 2025-12-31), down 11.7% year-over-year. The FCF margin was -12.4%.

MediPharm Labs Corp. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 10 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

LABS.TO free cash flow · 8 questions

MediPharm Labs Corp. free cash flow was −$5.6M for FY2025, down 11.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$3.3M.

LABS.TO free cash flowLABS.TO FCFLABS.TO FCF 2025LABS.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · MediPharm Labs Corp. · MediPharm Labs Corp. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026